Key Statistics
About Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Analyst Ratings
View All →| Date | Firm | Rating |
|---|---|---|
| Dec 8, 2025 | UBS | |
| Nov 13, 2025 | Barclays | |
| Nov 13, 2025 | RBC Capital | |
| Nov 13, 2025 | Cantor Fitzgerald | |
| Oct 17, 2025 | HC Wainwright & Co. |